SANA Company Profile and Key Details
NASDAQ : SANA
Sana Biotechnology
$2.68
-0.09-3.25%
Open: 4:00 PM63.97
BESG ScoreESG Rating
Price Chart
Stock Price Today
Sana Biotechnology, Inc. (SANA) stock declined over -3.25%, trading at $2.68 on NASDAQ, down from the previous close of $2.77. The stock opened at $2.77, fluctuating between $2.67 and $2.85 in the recent session.
Stock Snapshot
2.77
Prev. Close
745.82M
Market Cap
2.67
Day Low
-2.91
P/E Ratio
-0.92
EPS (TTM)
-1.39
Cash Flow per Share
2.77
Open
278.29M
Number of Shares
2.85
Day High
65.76%
Free Float in %
1.46
Book Value
2.23M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 12, 2026 | 2.77 | 2.85 | 2.67 | 2.68 | 2.25M |
| Jun 11, 2026 | 2.82 | 2.88 | 2.74 | 2.77 | 2.95M |
| Jun 10, 2026 | 2.76 | 2.91 | 2.76 | 2.82 | 2.68M |
| Jun 09, 2026 | 2.73 | 2.92 | 2.65 | 2.82 | 8.72M |
| Jun 08, 2026 | 2.74 | 2.75 | 2.61 | 2.69 | 3.34M |
| Jun 05, 2026 | 2.93 | 2.95 | 2.66 | 2.68 | 4.65M |
| Jun 04, 2026 | 3.13 | 3.25 | 2.94 | 2.96 | 4.19M |
| Jun 03, 2026 | 3.23 | 3.25 | 3.08 | 3.12 | 2.57M |
| Jun 01, 2026 | 3.29 | 3.38 | 3.14 | 3.21 | 3.4M |
| May 29, 2026 | 3.13 | 3.33 | 3.07 | 3.30 | 5.01M |
| May 28, 2026 | 3.04 | 3.20 | 2.98 | 3.13 | 6.17M |
| May 27, 2026 | 3.06 | 3.23 | 3.01 | 3.06 | 3.54M |
| May 26, 2026 | 3.08 | 3.17 | 2.97 | 3.05 | 4.04M |
| May 22, 2026 | 3.19 | 3.25 | 3.06 | 3.07 | 4.18M |
| May 21, 2026 | 3.05 | 3.18 | 3.01 | 3.15 | 2.06M |
| May 20, 2026 | 3.06 | 3.17 | 3.06 | 3.11 | 2.94M |
| May 19, 2026 | 2.97 | 3.15 | 2.91 | 3.06 | 3.39M |
| May 18, 2026 | 3.07 | 3.15 | 2.98 | 3.04 | 2.95M |
| May 15, 2026 | 3.05 | 3.11 | 2.96 | 3.07 | 3.7M |
| May 14, 2026 | 3.23 | 3.28 | 3.08 | 3.14 | 22.77M |
Contact Details
About Company
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Company Information
| Employees | 194 |
| Beta | 1.96 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-5.42-0.60%
argenx SE$893.52REGN0.66+0.11%
Regeneron Pharmaceuticals, Inc.$612.14UTHR0.56+0.10%
United Therapeutics Corporation$545.96MDGL6.49+1.37%
Madrigal Pharmaceuticals, Inc.$480.77VRTX-0.115-0.03%
Vertex Pharmaceuticals Incorporated$444.93KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83KRYS-3.575-1.11%
Krystal Biotech, Inc.$317.97ALNY-6.54-2.26%
Alnylam Pharmaceuticals, Inc.$282.85PRAX18.6+7.50%
Praxis Precision Medicines, Inc.$266.58LGND0.97+0.38%
Ligand Pharmaceuticals Incorporated$255.54Company Overview
Sana Biotechnology, Inc. (NASDAQ:SANA) closed at $2.68 USD, losing -$0.09 (-3.25%) from the previous close of $2.77. The stock is currently mid-range between its 52-week high and low $2.43 and $6.55. With a market capitalization of about $745.82 million, Sana Biotechnology, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.16). Key stats such as the average daily volume over the past year has been around 3.75 million shares, volume is running light vs its 52-week average. Headquartered in Seattle, WA, Sana Biotechnology, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven D. Harr, the company employs approximately 194 people and listed since February 04, 2021. Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells.
Technical Performance
SANA has shown mixed momentum, losing 0.0% over the past week and -8.95% over the past quarter, though year-to-date performance is up 12.53%. Short-term trend indicators are mixed aligned (SMA20 4.62%, SMA50 -2.52%, SMA200 11.81%). The stock’s 14-day RSI is 52.13 (neutral), while the ATR of 0.29 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -34.81% below its high and over 238.89% above its low. Average 10-day trading volume of 3.92 million shares is in line with the 3-month average of 3.80 million, indicating normal recent market interest.
Valuation Metrics
Sana Biotechnology, Inc. trades at a P/E ratio of -3.12, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 6.33 trading at moderately above to book value. The P/FCF stands at -5.67, also above market averages.
Dividend & Fair Value
Sana Biotechnology, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.03. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Sana Biotechnology, Inc. generated EPS of -$0.97 over the past year. Five-year average earnings growth is -10.6%. Wall Street analysts project EPS growth of 19.3% annually over the next five years. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at -$0.14. Next year's EPS is expected at $29.73. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $5.00. The high target offers 347.76% upside. The low target suggests 86.57% downside. The mean target is $7.56. This offers 182.09% upside. Sana Biotechnology, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 11, 2026, missed forecasts by -6.67%. The prior quarter beat by 23.08%. Over the last six quarters, Apple has recorded several small beats. These include -8.0% in March 17, 2025.
Shareholding & Insider Activity
Sana Biotechnology, Inc. has 253.89 million shares outstanding. The public float is 155.38 million shares, elevated short interest at 39.14% of float. This equals 33.35 million shares. The short ratio is 5.55 days. Institutional investors hold 80.75% of the float. Insiders own 6.83%. CRANDELL KEITH holds 10.67 million shares, NELSEN ROBERT has 10.67 million shares and ARCH Venture Fund X, L.P. has 10.67 million shares.
Price Forecast & Outlook
Our AI price prediction model suggests that Sana Biotechnology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.34%, with price expected at $2.51 by June 26, 2026, within a range of $2.32 to $2.70 3-Month Outlook: Projected fall of -76.87%, reaching $0.62 by September 10, 2026, with a range of $0.43 to $0.77. 1-Year Outlook: Projected loss of -14.18%, with price at $2.30 by June 11, 2027, within a range of $0.00 to $0.02.
Key Takeaways
Sana Biotechnology, Inc. (NASDAQ:SANA) shares are up 12.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Sana Biotechnology, Inc. trading at a premium to the broader market with a P/E of -3.12. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $10.05, suggesting 275.0% upside. Our AI forecast model points to short-term weakness (-6.34% over two weeks), a medium-term fall (-76.87% over three months), and a longer-term loss (-14.18% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Sana Biotechnology, Inc. (SANA) stock price?
Sana Biotechnology, Inc. (NASDAQ: SANA) stock price is $2.68 in the last trading session. During the trading session, SANA stock reached the peak price of $2.85 while $2.67 was the lowest point it dropped to. The percentage change in SANA stock occurred in the recent session was -3.25% while the dollar amount for the price change in SANA stock was - $0.09.
SANA's industry and sector of operation?
The NASDAQ listed SANA is part of Biotechnology industry that operates in the broader Healthcare sector. Sana Biotechnology, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of SANA?
Dr. Edward Rebar Ph.D.
Senior Vice President & Chief Technology Officer
Ms. Shanna Clouse Peek
Senior Vice President & Head of Corporation Operations
Dr. Sunil Agarwal M.D.
Executive Vice President, Head of Devel. & Chief Medical Officer
Ms. Donna Dambach D.V.M., Ph.D.
Senior Vice President & Head of Devel. Sciences
Dr. Richard C. Mulligan Ph.D.
Executive Vice Chairman & Head of SanaX
Dr. Steven D. Harr M.D.
Pres, Chief Executive Officer & Director
Brittany Mccleery
Accounting Mang.
Mr. Nathan Hardy M.B.A.
Executive Vice President & Chief Financial Officer
Dr. Sonja Schrepfer M.D., Ph.D.
Senior Vice President & Head of Hypoimmune Platform
Mr. Christian Hordo M.B.A.
Executive Vice President & Chief Bus. Officer
Mr. Bernard J. Cassidy J.D.
Executive Vice President, Gen. Counsel & Corporation Sec.
Mr. Paul Brunetta M.D.
Senior Vice President and Head of Clinical & Translational Science
Ms. Robin Andrulevich
Executive Vice President & Chief People Officer
Senior Vice President & Chief Technology Officer
Ms. Shanna Clouse Peek
Senior Vice President & Head of Corporation Operations
Dr. Sunil Agarwal M.D.
Executive Vice President, Head of Devel. & Chief Medical Officer
Ms. Donna Dambach D.V.M., Ph.D.
Senior Vice President & Head of Devel. Sciences
Dr. Richard C. Mulligan Ph.D.
Executive Vice Chairman & Head of SanaX
Dr. Steven D. Harr M.D.
Pres, Chief Executive Officer & Director
Brittany Mccleery
Accounting Mang.
Mr. Nathan Hardy M.B.A.
Executive Vice President & Chief Financial Officer
Dr. Sonja Schrepfer M.D., Ph.D.
Senior Vice President & Head of Hypoimmune Platform
Mr. Christian Hordo M.B.A.
Executive Vice President & Chief Bus. Officer
Mr. Bernard J. Cassidy J.D.
Executive Vice President, Gen. Counsel & Corporation Sec.
Mr. Paul Brunetta M.D.
Senior Vice President and Head of Clinical & Translational Science
Ms. Robin Andrulevich
Executive Vice President & Chief People Officer
How SANA did perform over past 52-week?
SANA's closing price is 11.2% higher than its 52-week low of $2.43 where as its distance from 52-week high of $6.55 is -59.08%.
How many employees does SANA have?
Number of SANA employees currently stands at 194.
Link for SANA official website?
Official Website of SANA is: https://www.sana.com
How do I contact SANA?
SANA could be contacted at phone 206 701 7914 and can also be accessed through its website. SANA operates from 188 East Blaine Street, Seattle, WA 98102, United States.
How many shares of SANA are traded daily?
SANA stock volume for the day was 2.23M shares. The average number of SANA shares traded daily for last 3 months was 3.75M.
What is the market cap of SANA currently?
The market value of SANA currently stands at $745.82M with its latest stock price at $2.68 and 278.29M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep